Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethylcarbamazine is a synthetic small molecule anthelmintic drug used primarily for the treatment and prevention of filarial diseases such as lymphatic filariasis (caused by Wuchereria bancrofti, Brugia malayi or Brugia timori), loiasis (caused by Loa loa), tropical pulmonary eosinophilia and other related parasitic infections. It works by inhibiting arachidonic acid metabolism in microfilariae—specifically targeting the 5-lipoxygenase and cyclooxygenase pathways—making the parasites more susceptible to phagocytosis and immune attack. The drug does not directly kill adult worms but sensitizes microfilariae to host immune responses. Diethylcarbamazine is no longer FDA-approved or commercially available in the United States but remains widely used globally for mass drug administration programs against lymphatic filariasis[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethylcarbamazine.